comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Bridging the gap between GLP1-receptor outcomes: evidence for the role of | Cardiovascular Diabetology The Role of Glucagon-Like Peptide-1

Some patients may switch from tirzepatide to semaglutide because of tolerance, side effects, cost, availability or provider recommendation

What This New Study Found Between Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound), and Stroke Risk A new cohort study published July 2025 in JAMA Network Open followed over 60,000 adults with both type 2 diabetes and obesity

Gradual Dose Increase: Sometimes, starting with a lower dose of semaglutide and gradually increasing it can help your body adjust to the medication

[9] According to the FDA prescribing information, nausea occurred in 12-24% of patients, vomiting in 2-11%, and diarrhea in 7-17%, with rates varying by dose (5 mg, 10 mg, or 15 mg weekly)